I. I. Bocharova

I. I. Bocharova

Auto-generated profile, based on publicly available information

I. I. Bocharova

Moscow Regional Scientific Research Institute of Obstetrics and Gynecology named after Academician V. I. Krasnopolsky; Moscow Regional Research Clinical Institute named after M. F. Vladimirsky

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2023 in Russian Bulletin of Obstetrician-Gynecologist
Verified
Journal Article
Closed access
AYA.A. Yakubina
A.A. Yakubina
AAA.N. Aksenov
A.N. Aksenov
IBI.I. Bocharova
I.I. Bocharova
MTM.V. Troitskaya
M.V. Troitskaya
MBM.YU. Bukina
M.YU. Bukina
EDE.V. Dulaeva
E.V. Dulaeva
A review of the literature is devoted to the information on the effect of a new coronavirus infection (COVID-19) on the course of pregnancy, the possibility of vertical transmission of the virus from mother to fetus and the condition of the neonates. A review of the literature reveals similarities in the clinical manifestations of COVID-19 in pregnant and non-pregnant women. However, pregnant women are reported to have an increased risk of ICU admission and need for ventilatory support in various countries. Transplacental transmission from the mother to the fetus has been widely reported. Preterm birth is now common among pregnancy outcomes, especially in women who have had moderate to severe COVID-19. In the assessment of newborns born to mothers with COVID-19, prematurity, hypoxic conditions and respiratory disorders predominated. Further study of the pathogenesis of a new coronavirus infection is necessary to determine factors of possible vertical transmission, the effect on fetal growth and development, the course of pregnancy and labor, and peculiarities of the early neonatal period in infants whose mothers had had this infection in the first and second trimesters of pregnancy.

1 January 2022 in Russian Bulletin of Obstetrician-Gynecologist
Verified
Journal Article
Closed access
AAA.N. Aksenov
A.N. Aksenov
LLL.S. Logutova
L.S. Logutova
IBI.I. Bocharova
I.I. Bocharova
MTM.V. Troitskaya
M.V. Troitskaya
VVV.A. Vlasova
V.A. Vlasova
MBM.Yu. Bukina
M.Yu. Bukina

1 January 2021 in Voprosy Ginekologii, Akušerstva i Perinatologii
Verified
Journal Article
Closed access
IBI.I. Bocharova
I.I. Bocharova
NZN.V. Zarochentseva
N.V. Zarochentseva
AAA.N. Aksenov
A.N. Aksenov
VMV.V. Malinovskaya
V.V. Malinovskaya
EVE.N. Vyzhlova
E.N. Vyzhlova
TST.A. Semenenko
T.A. Semenenko
Objective. To study the prophylactic effectiveness of the intranasal application of VIFERON®, the gel for external and local use (interferon α-2b) 36,000 IU/g, against ARVI in newborns and their mothers during the COVID-19 pandemic. Patients and methods. A total of 227 mother–newborn couples were examined, randomized into three groups: Group 1 (n = 63) – the VIFERON® gel was used according to the instructions; Group 2 (n = 50) – the VIFERON® gel was used in violation of the recommended scheme; Group 3 (control, n = 114) – did not use the medication. The main criteria for the effectiveness of prevention were: the incidence of ARVI in a mother–child couple for 3 months after inclusion in the study; the duration and severity of clinical symptoms of the disease; evaluation of the frequency of adverse events associated with the use of the drug under study. Results. The use of the VIFERON® gel led to a decrease in the number of ARVI cases in mothers (11.1 and 14.9%) and newborns (7.9 and 20.2%; p = 0.034) in Group 1 compared with Group 3, respectively, as well as to a significant reduction in the duration of the disease (p = 0.001), a decrease in the severity of clinical symptoms: the level of hyperthermia (p = 0.015), the duration of febrile (p = 0.021), cough (p = 0.032), rhinitis (p = 0.033). There were no statistically significant differences between these indicators in Groups 2 and 3, which requires to follow drug instructions in order to achieve the maximum effect. The timing of onset of diseases in Group 1 in the third month of observation from the beginning of drug administration makes it possible to justify the need for repeated courses of prophylaxis at high risk of respiratory diseases. In 100% of cases, the drug was well tolerated, and there were no adverse effects. Conclusion. The high preventive efficacy and safety of interferon α-2b with antioxidants in the form of gel for external and local use (VIFERON®, gel) in newborns and their mothers against ARVI were proved, which makes it possible to recommend its use to prevent the new coronavirus infection COVID-19 in newborns and confirms the validity of its inclusion in clinical guidelines for the treatment of COVID-19 in children. Key words: prevention, ARVI, interferon α-2b with antioxidants, VIFERON® gel, mother–newborn, COVID-19

30 January 2024 in Russian Bulletin of Obstetrician-Gynecologist
Verified
Journal Article
Closed access
EEE.B. Efimkova
E.B. Efimkova
SNS.V. Novikova
S.V. Novikova
EDE.V. Dulaeva
E.V. Dulaeva
MIM.A. Ignat’eVa
M.A. Ignat’eVa
NBN.V. Biryukova
N.V. Biryukova
EPE.V. Pel’sHe
E.V. Pel’sHe
Objective. To analyze obstetric and perinatal outcomes in pregnant women with concomitant respiratory diseases who had acute respiratory infections during gestation. Material and methods. Sixty pregnant women with bronchial asthma of moderately severe course with acute respiratory infection during gestation were examined and delivered. Retrospectively, they were divided into two groups of 30 patients each: Group 1 consisted of patients who had an acute respiratory infection before 16 weeks of gestation, and Group 2 included pregnant women who became ill at 16—30 weeks of gestation. The comparison group (group 3) consisted of 20 pregnant women with bronchial asthma without acute inflammatory diseases during gestation. General clinical examination, extended study of the hemostasis system, hormones of fetoplacental complex and interferon status, acid-base state of capillary blood, saturation, ultrasound and Doppler parameters in dynamics were investigated. Results. It was shown that exacerbation of bronchial asthma during pregnancy was significantly more frequent in the main groups: group 1 — in 70%, group 2 — in 53.3%, group 3 — in 30%. This correlated with the frequency of obstetric and perinatal complications. In Group 1, the Apgar score at birth in 43.3% of newborns was less than 8 points, which was 2.6 times more frequent than in Group 2. Fetal growth retardation in group 1 was diagnosed in 30% of children, which was probably associated with the formation of PI of infectious genesis at an earlier gestational age than in group 2. Conclusion. The obtained results indicate a negative effect of acute respiratory infection on the course of pregnancy in patients with respiratory diseases regardless of the severity of acute respiratory infection. This requires clarification of pathogenetic mechanisms of development of these complications and optimization of management of this contingent of patients.

22 October 2024 in Russian Bulletin of Obstetrician-Gynecologist
Verified
Journal Article
Closed access
AKA.A. Kossova
A.A. Kossova
AAA.N. Aksenov
A.N. Aksenov
IBI.I. Bocharova
I.I. Bocharova
AYA.A. Yakubina
A.A. Yakubina
EUE.YU. Upryamova
E.YU. Upryamova
This review article presents the history of obstetric anesthesiology development, considers the methods and effects of non-medication anesthesia of labor, discusses the influence of narcotic and non-narcotic analgesics, neuroaxial methods of anesthesia and inhalation anesthesia on the fetus and perinatal outcomes.

15 April 2026 in Лечащий врач
Verified
Journal Article
Open access
PDF file
MSM.N. Shakaya
M.N. Shakaya
IBI.I. Bocharova
I.I. Bocharova
ТБТ. А. Бокова
Т. А. Бокова
Background. Neonatal hyperammonemia is a condition caused by an increased content of ammonia in the blood of a newborn, both as a result of certain hereditary metabolic diseases and occurring against the background of severe pathology of the perinatal period. Neonatal hyperammonemia is defined as serum ammonia concentration exceeding 100 μmol/L for full-term infants and exceeding 150 μmol/L for preterm infants. A level exceeding 360 μmol/L (600 micrograms per deciliter (mcg/dL)) is considered a critical threshold, which is associated with a high risk of irreversible changes in the brain, liver, kidneys and other organ systems, and requires immediate initiation of extracorporeal detoxification methods. Upon entering the central nervous system, ammonia triggers a cascade of pathological reactions. The pivotal event in this case will be the overproduction of glutamine in astroglia. The relevance of neonatal hyperammonemia is underscored not only by its life-threatening nature and by the complexity of timely diagnosis due to the non-specific clinical presentation, but also by a significant risk of multiple organ failure and fatal outcome in the case of the delayed correction of hyperammonemia. Regardless of the cause, neonatal hyperammonemia can become life-threatening and lead to irreversible damage to cells of the central nervous system, liver and other organs. Results. This review analyzes the current understanding of the etiopathogenesis of neonatal hyperammonemia, including the mechanisms of neuro- and cytotoxicity, the classification of etiological factors, and clinical semiotics. Special attention is paid to the differential diagnostic algorithm, which makes it possible to distinguish between primary defects of the urea cycle, organic acidemia and transient conditions. Intensive care protocols, including pharmacological methods of ammonia binding, indications for extracorporeal detoxification, and a long-term patient management strategy are considered in detail. It is emphasized that the outcome of the disease is directly determined by the timeliness of diagnosis and the immediate initiation of pathogenetic therapy.